Eli Lilly's Oral Pill Maintains Weight Loss Post-Injections; FDA Approval Sought

• Eli Lilly's orforglipron pill helped patients maintain most weight loss after switching from injectable GLP-1 treatments like Zepbound and Wegovy.
• The company submitted an application to the FDA for approval of the daily GLP-1 pill for obesity treatment, with priority review granted.
• The late-stage trial showed the pill met its primary goal, demonstrating superior weight-loss maintenance compared to placebo.
• It offers a needle-free maintenance option, addressing weight regain often seen after discontinuing injectable GLP-1 therapies.
• The pill's safety profile was consistent with earlier studies, showing mild to moderate gastrointestinal issues as common side effects.

Why It Matters: Eli Lilly's new oral pill offers a promising needle-free option for long-term weight loss maintenance.